| 2026-08-17 | Press release | Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Nam |
| 2026-08-14 | Press release | Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update |
| 2026-08-12 | Press release | Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibioti |
| 2026-08-10 | Press release | Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA |
| 2026-08-03 | Press release | FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Inc |
| 2026-07-08 | Press release | Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Bu |
| 2026-06-16 | Press release | Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership |
| 2026-05-12 | Press release | Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update |
| 2026-05-12 | Press release | PDF |
| 2026-05-04 | Press release | Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Glob |
| 2026-04-29 | Press release | Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase |
| 2026-04-20 | Press release | Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Busine |
| 2026-04-16 | Press release | Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Unde |
| 2026-04-16 | Press release | Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Ru |
| 2026-03-30 | Press release | Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors |
| 2026-03-13 | Press release | Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update |
| 2026-03-09 | Press release | Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift t |
| 2026-02-16 | Press release | Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call a |
| 2026-02-02 | Press release | USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors |